Olenox Industries Completes Acquisition of PsyLinks Neurotech Corp. to Expand its Applied Intelligence Capabilities

Rhea-AI Summary

Olenox Industries (NASDAQ:OLOX) has completed the acquisition of PsyLinks Neurotech Corp., an applied intelligence and neurotechnology company founded by Dr. Michael McLaren-Gradinaru and Dr. Ford Burles. Under a Share Exchange Agreement, Olenox acquired all outstanding PsyLinks shares in exchange for approximately $500,000 of Olenox restricted common stock, making PsyLinks a wholly owned subsidiary.

According to Olenox, PsyLinks develops technologies to collect, analyze, and interpret complex operational data, which the company believes supports its strategy of integrating energy production, industrial infrastructure, and digital technologies. As part of the transaction, Dr. McLaren-Gradinaru and Dr. Burles join Olenox as Vice President of Technology and Vice President of Product Development. The deal may constitute a related-party transaction due to a familial relationship between one seller and Olenox’s Chairman and was reviewed and approved by the independent directors, with the interested director abstaining.

Positive

• Acquisition of PsyLinks for approximately $500,000 in restricted stock
• PsyLinks adds applied AI and data analytics capabilities for operational data
• PsyLinks becomes a wholly owned subsidiary, aligning technology under Olenox
• Founders appointed VP of Technology and VP of Product Development at Olenox
• All-stock consideration preserves Olenox’s cash by using equity as payment

Negative

• Transaction may be a related-party deal under SEC rules due to family tie
• Equity payment of about $500,000 in restricted shares causes shareholder dilution

News Explained

Existing common holders face a completed acquisition funded with approximately $500,000 of restricted Olenox stock, with dilution magnitude undisclosed.

The July 13 release says Olenox Industries has completed its acquisition of all outstanding PsyLinks shares, making PsyLinks a wholly owned subsidiary; the consideration was approximately $500,000 of restricted Olenox common stock.

Because the consideration is common stock rather than cash, the transaction transfers shares to the PsyLinks sellers and can reduce existing holders’ ownership; the release does not provide the share count or resulting ownership percentage. The release also says the acquisition may constitute a related-party transaction because of a familial relationship involving one seller and Olenox’s chairman, and that independent directors approved it with the interested director abstaining.

Market reaction after PsyLinks Neurotech acquisition: OLOX -4.36% in the Jul 13 session

-4.36% 29.6x vol

25 alerts

-4.36% Session close to close

+42.2% Peak Tracked

-20.9% Trough Tracked

$5.90M Market Cap

29.6x Rel. Volume

In the Jul 13 session, OLOX declined 4.36%, reflecting a moderate negative market reaction. Argus tracked a peak move of +42.2% during that session. Argus tracked a trough of -20.9% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 29.6x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Olenox’s completion of the $500,000 all-stock PsyLinks acquisition adds neurotechnology and applied ...

Analysis

Olenox’s completion of the $500,000 all-stock PsyLinks acquisition adds neurotechnology and applied intelligence capabilities while introducing related-party scrutiny. Prior deals show mixed share responses; governance oversight and execution on integrating these digital tools into energy assets remain key watchpoints.

Key Figures

Purchase price: $500,000

1 metrics

Purchase price $500,000 Stock consideration for PsyLinks acquisition

Previous Acquisition Reports

3 past events · Latest: May 28 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	Digital ventures acquisition	Positive	+0.6%	Closed CS Digital Ventures deal, adding 35 MW capacity and digital platform.
Apr 10	Midstream LOI amendment	Positive	+1.8%	Amended Vivakor midstream LOI with $36M valuation and EBITDA support terms.
Jan 29	Midstream LOI announcement	Positive	-7.6%	Signed LOI to acquire Vivakor midstream business valued at $36M with EBITDA guarantee.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Acquisition-related headlines have produced mixed but modest average stock moves, with one notably negative reaction alongside smaller positive days.

Key Terms

neurotechnology, applied intelligence, restricted common stock, wholly-owned subsidiary, +1 more

5 terms

neurotechnology technical

"PsyLinks is a neurotechnology and applied intelligence company that develops"

Neurotechnology encompasses tools and methods that interface with the brain to monitor, understand, or influence its activity. It matters to investors because advancements in this field can lead to breakthroughs in healthcare, mental health treatments, and brain-computer interfaces, potentially creating new markets and disruptive innovations. Think of it as developing new ways to read or communicate with the brain, opening opportunities for growth and technological progress.

applied intelligence technical

"PsyLinks Neurotech Corp. ("PsyLinks"), an applied intelligence company founded"

Applied intelligence is the practical use of data, automation and machine learning to solve real business problems and improve decisions—like turning a complicated map into a GPS that gives step‑by‑step routes. For investors, it matters because it can boost revenue, cut costs, speed innovation and make operations more predictable; companies that successfully apply intelligence often gain measurable competitive advantages and clearer growth or risk signals.

restricted common stock financial

"in exchange for approximately $500,000 of shares of restricted common stock"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

wholly-owned subsidiary financial

"Psylinks will now operate as a wholly-owned subsidiary of Olenox."

A wholly-owned subsidiary is a company whose entire ownership is held by another company, called the parent, so the parent controls all shares, board appointments and major decisions. For investors this matters because the subsidiary’s profits, losses, assets and liabilities are treated as part of the parent’s financial picture, affecting valuation and risk exposure — imagine a parent owning a single storefront outright and consolidating its receipts and bills into the parent’s books.

related-party transaction regulatory

"The acquisition may constitute a related-party transaction under applicable SEC rules"

A related-party transaction is a deal, payment or transfer of value between a company and people or entities closely connected to its managers, directors or major owners—think of a business hiring a company owned by the CEO’s sibling. Investors care because such deals can be biased, overprice goods or hide conflicts of interest, affecting profits and trust; clear disclosure and fair terms help ensure the company is run in shareholders’ best interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Acquisition adds applied artificial intelligence and data analytics capabilities to support Olenox's technology and digital infrastructure strategy

CONROE, TX / ACCESS Newswire / July 13, 2026 / Olenox Industries Inc. (NASDAQ:OLOX) ("Olenox" or the "Company"), a vertically integrated U.S. energy company, today announced the completion of its acquisition of PsyLinks Neurotech Corp. ("PsyLinks"), an applied intelligence company founded by neuroscientists Dr. Michael McLaren-Gradinaru and Dr. Ford Burles.

Under the terms of the Share Exchange Agreement, Olenox acquired all of the outstanding shares of PsyLinks in exchange for approximately $500,000 of shares of restricted common stock of Olenox. Psylinks will now operate as a wholly-owned subsidiary of Olenox. As part of the acquisition, Dr. Michael McLaren-Gradinaru and Dr. Ford Burles have joined Olenox as Vice President of Technology and Vice President of Product Development, respectively.

PsyLinks is a neurotechnology and applied intelligence company that develops technologies to collect, analyze, and interpret complex operational data. Olenox believes these capabilities complement its strategy of integrating energy production, industrial infrastructure, and digital technologies to enhance operational visibility, improve decision-making, and support future technology initiatives.

"Shareholders should ask one question about any acquisition we make: how does this make us money?" said Mike McLaren, Chairman and Chief Executive Officer of Olenox. "PsyLinks strengthens our strategy of creating more value from the energy and infrastructure we own by applying intelligence across our operations. We believe its technology can help improve how we produce, manage, and utilize our energy and infrastructure assets while supporting the growth of our digital infrastructure initiatives. This acquisition is another step in building a more integrated energy and technology platform."

The acquisition may constitute a related-party transaction under applicable SEC rules due to a familial relationship between one of the sellers and the Company's Chairman. The transaction was reviewed and approved by the independent members of the Company's Board of Directors, with the interested director abstaining from the approval.

About Olenox Industries Inc.
Olenox Industries Inc. is a vertically integrated U.S. energy company operating across multiple business lines, including oil and gas, energy services and energy technologies, including the proprietary Olenox process. The Company is focused on acquiring, optimizing and scaling energy-related infrastructure and operating assets across key U.S. markets, with a strategic focus on bringing low-cost natural gas to high-value end uses, including digital infrastructure and next-generation compute.

About PsyLinks Neurotech Corp.
PsyLinks is a neurotechnology and applied intelligence company that develops closed-loop systems to capture synchronized multi-modal data, interpret it in real time, and provide actionable insights for complex operational environments. PsyLinks operates as a wholly owned subsidiary of Olenox Industries Inc. and is expected to support the Company's applied intelligence initiatives. For more information, please visit the PsyLinks Neurotech website: https://psylinks.ca.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable U.S. federal securities laws. Forward-looking statements include, without limitation, statements regarding the expected benefits of the acquisition of PsyLinks Neurotech Corp., the integration of PsyLinks' technology across the Company's operations, the development and deployment of closed-loop intelligence, monitoring, optimization and automation capabilities, and the future business, operations and financial performance of the combined company. These statements are based on current expectations and assumptions and are subject to risks, uncertainties and other factors, many of which are outside of the Company's control, that could cause actual results to differ materially. Such factors include, among others, the ability to integrate PsyLinks' technology and personnel, the timing and success of deployments across the Company's assets, variability in customer demand and pricing, regulatory developments, and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Investor and Media Contacts:
Olenox Industries Inc. | Investor Relations: investors@olenox.com

SOURCE: Olenox Industries Inc.

View the original press release on ACCESS Newswire

FAQ

What did Olenox Industries (NASDAQ:OLOX) acquire with the PsyLinks Neurotech transaction in July 2026?

Olenox Industries acquired all outstanding shares of PsyLinks Neurotech in exchange for about $500,000 of restricted common stock. According to Olenox, PsyLinks brings applied intelligence and neurotechnology for collecting and analyzing complex operational data across its energy and infrastructure operations.

How much did Olenox Industries (OLOX) pay for PsyLinks Neurotech and what was the deal structure?

Olenox paid approximately $500,000 in restricted common stock to acquire all PsyLinks shares. According to Olenox, the transaction was executed through a Share Exchange Agreement, making PsyLinks a wholly owned subsidiary without requiring cash consideration from the company.

How does the PsyLinks acquisition support Olenox Industries’ applied intelligence and digital infrastructure strategy?

The acquisition adds PsyLinks’ technologies for collecting, analyzing, and interpreting complex operational data. According to Olenox, these capabilities are intended to complement its integrated energy, industrial infrastructure, and digital technology strategy to improve operational visibility, decision-making, and future digital infrastructure initiatives.

What management changes result from the Olenox Industries (OLOX) acquisition of PsyLinks Neurotech?

As part of the acquisition, PsyLinks founders Dr. Michael McLaren-Gradinaru and Dr. Ford Burles join Olenox. According to Olenox, they assume roles as Vice President of Technology and Vice President of Product Development, strengthening internal leadership for technology and product initiatives.

Is the Olenox Industries acquisition of PsyLinks considered a related-party transaction under SEC rules?

The acquisition may constitute a related-party transaction because one PsyLinks seller has a familial relationship with Olenox’s Chairman. According to Olenox, independent board members reviewed and approved the transaction, and the interested director abstained from the approval process.

What does the PsyLinks acquisition mean for Olenox Industries (OLOX) shareholders?

Shareholders see Olenox issue about $500,000 in restricted stock to acquire PsyLinks, causing some dilution. According to Olenox, PsyLinks’ applied intelligence capabilities are expected to support value creation across its energy, infrastructure, and digital initiatives over time.